Figures
- FIGURE 1
Consolidated standards of reporting trials participant disposition. HBPR: home-based pulmonary rehabilitation; PR: pulmonary rehabilitation.
Tables
- TABLE 1
Baseline characteristics of participants
Control HBPR p-value Participants 30 33 Female 18 (60) 16 (48.5) 0.360 Age years 49.27±14.10 44.42±16.16 0.209 BMI kg·m−2 24.02±2.91 23.96±2.56 0.933 MRC score 2.90±0.92 2.48±1.03 0.097 Aetiology Idiopathic 15 (50) 7 (21) Recurrent pneumonia 6 (20) 9 (27) Gastro-oesophageal reflux disease 4 (13) 1 (3) Other causes 5 (17) 16 (49) MRC score 0.366 1 1 (3.3) 6 (18.2) 2 10 (33.3) 11 (33.3) 3 11 (36.7) 11 (33.3) 4 7 (23.3) 4 (12.1) 5 1 (3.3) 1 (3.0) FACED score 2.50±1.04 2.27±1.23 0.431 Mild/moderate severity 15 (50)/15 (50) 16 (49)/17 (51) E-FACED score 2.57±1.19 2.45±1.37 0.730 Mild/moderate severity 24 (80)/6 (20) 26 (79)/7 (21) 0.905 Pseudomonas colonisation 14 (46.7) 10 (30.3) 0.189 FVC L 2.35±0.81 2.59±0.97 0.296 FVC % pred 68.90±20.57 72.30±21.89 0.527 FEV1 L 1.37±0.56 1.63±0.84 0.151 FEV1 % pred 51.21±0.56 55.15±27.19 0.535 FEV1/FVC 59.09±14.30 61.47±16.49 0.542 ISWT m 433.79±145.74 477.40±196.88 0.319 ESWT min 8.22±6.87 8.14±6.90 0.961 MIST total steps 115.92±71.74 141.94±93.89 0.230 Daily steps 6045±2731 7340±4754 0.186 Quadriceps strength kg-force 26.46±12.15 26.52±10.76 0.983 Data are presented as n, n (%) or mean±sd, unless otherwise stated. HBPR: home-based pulmonary rehabilitation; BMI: body mass index; MRC: Medical Research Council dyspnoea scale; FACED: forced expiratory volume in 1 s (FEV1), age, chronic colonisation by Pseudomonas aeruginosa, radiological extension and dyspnoea; E-FACED: FACED criteria plus exacerbation; FVC: forced vital capacity; ISWT: incremental shuttle walk test; ESWT: endurance shuttle walk test; MIST: modified incremental step test.
- TABLE 2
Change in clinical differences from baseline to 2 months and follow-up (6 months)
Within-group differences from baseline (95% CI) Between-group differences HBPR (n=33) Control (n=30) HBPR minus control End rehabilitation minus baseline (n=27) 6 months minus end rehabilitation (n=19) End rehabilitation minus baseline (n=28) 6 months minus end rehabilitation (n=18) End rehabilitation minus baseline 6 months minus end rehabilitation ISWT m 60.94±119.79 (21.84–100.04)* −32.39±50.63 (−80.08–10.49) −26.97±80.15 (−65.37–11.42) 31.55±131.74 (−13.67–78.85) 87.91 (32.98–142.85)# −63.94 (−129.87–1.99) ESWT min 4.62±5.43 (2.88–6.35)* −0.14±3.82 (−2.88–2.60) 0.26±3.34 (−1.44–1.96) 0.43±7.47 (−2.38–3.25) 4.36 (1.93–6.79)# −0.57 (−4.50–3.35) MIST total steps 66.11±87.86 (38.80–93.42)* −32.73±54.08 (−54.30– −11.16)¶ −15.24±40.47 (−42.02–11.54) −3.99±28.46 (−28.45–20.47) 81.35 (43.10–119.60)# −28.74 (−61.35–3.88) Daily steps 735.76±3114.20 (−275.40–1746.61) −815.90±4359.73 (−2501.33–869.54) −592.70±2032.41 (−1585.63–400.24) −834.05±2614.79 (−2565.67–897.57) 1328.45 (−88.72–2745.61) −18.15 (−2398.30–2434.59) Quadriceps strength kg-force 4.90±7.63 (2.24–7.56)* −3.06±8.67 (−6.78–0.66) −0.82±6.09 (−3.43–1.79) −0.24±7.19 (−4.07–3.58) 5.72 (1.99–9.45)# −2.82 (−8.15–2.51) Data are presented as mean±sd (95% CI). HBPR: home-based pulmonary rehabilitation; ISWT: incremental shuttle walk test; ESWT: endurance shuttle walk test; MIST: modified incremental step test. *: p<0.05 versus baseline; #: p<0.05 between groups; ¶: p<0.05 versus end rehabilitation.
- TABLE 3
Change in quality of life differences from baseline to 2 months and follow-up (6 months)
Within-group differences from baseline (95% CI) Between-group differences HBPR (n=33) Control (n=30) HBPR minus control End rehabilitation (n=27) 6 months (n=19) End rehabilitation (n=28) 6 months (n=18) End rehabilitation 6 months QoL-B (physical) 10.30±18.05 (2.79–17.80)* −10.11±18.78 (−18.26– −1.95)# −1.15±20.73 (−8.66–6.36) −1.76±15.94 (−10.39–6.86) 11.44 (0.83–22.06)¶ −8.34 (−20.21–3.53) QoL-B (role) 11.30±12.85 (4.84–17.76)* −5.58±12.74 (−11.09– −0.07)# −0.22±19.87 (−6.69–6.24) −1.24±10.67 (−7.06–4.59) 11.52 (2.38–20.66)¶ −4.34 (−12.36–3.67) QoL-B (vitality) 0.37±15.90 (−5.85–6.59) −11.79±16.74 (−19.18– −4.40)# −1.00±16.29 (−7.22–5.22) −2.24±14.81 (−10.05–5.58) 1.37 (−7.42–10.16) −9.55 (−20.31–1.21) QoL-B (emotional) 3.52±12.34 (−1.08–8.12) −0.89±12.98 (−5.83–7.62) −3.63±11.46 (−8.23–0.97) −4.41±15.90 (−11.52–2.70) 7.15 (0.65–13.65)¶ 5.31 (−4.48–15.10) QoL-B (social) 1.26±26.41 (−7.83–10.35) 1.68±17.82 (−7.24–10.61) −3.41±20.28 (−12.50–5.68) −0.06±20.53 (−9.49–9.38) 4.67 (−8.19–17.52) 1.74 (−11.24–14.73) QoL-B (treatment burden) −5.30±25.15 (−15.10–4.51) 5.68±19.69 (−4.92–16.29) −0.07±25.63 (−9.88–9.73) −2.71±25.76 (−13.92–8.51) −5.22 (−19.09–8.64) 8.39 (−7.04–23.82) QoL-B (health) −2.63±17.71 (−9.05–3.79) 9.84±18.64 (1.73–17.96)# −1.15±15.44 (−7.57–5.26) 8.65±15.91 (0.07–17.23)# −1.48 (−10.56–7.59) 1.20 (−10.62–13.01) QoL-B (respiratory) 3.04±11.31 (−1.93–8.00) −4.68±11.33 (−10.26–0.89) −0.56±14.23 (−5.52–4.41) −7.88±2.62 (−13.78– −1.99)# 3.59 (−3.43–10.61) 3.20 (−4.91–11.31) Data are presented as mean±sd (95% CI). HBPR: home-based pulmonary rehabilitation; QoL-B: Quality of Life Questionnaire Bronchiectasis. *: p<0.05 versus baseline; #: p<0.05 versus end rehabilitation; ¶: p<0.05 between groups.
